REFERENCES
1. Association for the Study of the Liver. Electronic address: [email protected], European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatocellular carcinoma. J Hepatol 2018;69:182-236.
2. Raoul JL, Forner A, Bolondi L, Cheung TT, Kloeckner R, de Baere T. Updated use of TACE for hepatocellular carcinoma treatment: how and when to use it based on clinical evidence. Cancer Treat Rev 2019;72:28-36.
3. Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol 2022;76:681-93.
4. Charriere B, Muscari F, Maulat C, et al. Outcomes of patients with hepatocellular carcinoma are determined in multidisciplinary team meetings. J Surg Oncol 2017;115:330-6.
5. Serper M, Taddei T, Mehta R, et al. Association of provider specialty and multidisciplinary care with hepatocellular carcinoma treatment and mortality. Gastroenterology 2017;152:1954-64.
6. Matsumoto MM, Mouli S, Saxena P, et al. Comparing real world, personalized, multidisciplinary tumor board recommendations with BCLC algorithm: 321-patient analysis. Cardiovasc Intervent Radiol 2021;44:1070-80.
7. Pelizzaro F, Haxhi S, Penzo B, et al. Transarterial chemoembolization for hepatocellular carcinoma in clinical practice: temporal trends and survival outcomes of an iterative treatment. Front Oncol 2022;12:822507.
8. Kudo M, Han KH, Ye SL, et al. A changing paradigm for the treatment of intermediate-stage hepatocellular carcinoma: asia-pacific primary liver cancer expert consensus statements. Liver Cancer 2020;9:245-60.
10. Lucatelli P, Burrel M, Guiu B, de Rubeis G, van Delden O, Helmberger T. CIRSE standards of practice on hepatic transarterial chemoembolisation. Cardiovasc Intervent Radiol 2021;44:1851-67.
11. Forsberg JO. Transient blood flow reduction induced by intra-arterial injection of degradable starch microspheres. Experiments on rats. Acta Chirurgica Scandinavica 1978;144:275-281.
12. Yamada R, Nakatsuka H, Nakamura K, et al. Super-selective arterial embolization in unresectable hepatomas (author’s transl). Nihon Igaku Hoshasen Gakkai zasshi 1979;39:540-3.
13. Taguchi T. Chemo-occlusion for the treatment of liver cancer. A new technique using degradable starch microspheres. Clin Pharmacokinet 1994;26:275-91.
14. Kirchhoff TD, Rudolph KL, Layer G, et al. Chemoocclusion
15. Pieper CC, Meyer C, Vollmar B, Hauenstein K, Schild HH, Wilhelm KE. Temporary arterial embolization of liver parenchyma with degradable starch microspheres (EmboCept®S) in a swine model. Cardiovasc Intervent Radiol 2015;38:435-41.
16. Ebert M, Ebert J, Berger G. Intravital microscopic research of microembolization with degradable starch microspheres. J Drug Deliv 2013;2013:242060.
17. Håkansson L, Håkansson A, Morales O, Thorelius L, Warfving T. Spherex (degradable starch microspheres) chemo-occlusion-enhancement of tumor drug concentration and therapeutic efficacy: an overview. Semin Oncol 1997;24:S6-100.
18. Cappelli A, Pettinato C, Golfieri R. Transarterial radioembolization using yttrium-90 microspheres in the treatment of hepatocellular carcinoma: a review on clinical utility and developments. J Hepatocell Carcinoma 2014;1:163-82.
19. Liapi E, Geschwind JF. Intra-arterial therapies for hepatocellular carcinoma: where do we stand? Ann Surg Oncol 2010;17:1234-46.
20. Aronsen KF, Hellekant C, Holmberg J, Rothman U, Teder H. Controlled blocking of hepatic artery flow with enzymatically degradable microspheres combined with oncolytic drugs. Eur Surg Res 1979;11:99-106.
21. Wiggermann P, Wohlgemuth WA, Heibl M, et al. Dynamic evaluation and quantification of microvascularization during degradable starch microspheres transarterial Chemoembolisation (DSM-TACE) of HCC lesions using contrast enhanced ultrasound (CEUS): a feasibility study. Clin Hemorheol Microcirc 2013;53:337-48.
22. Yamasaki T, Saeki I, Harima Y, et al. Effect of transcatheter arterial infusion chemotherapy using iodized oil and degradable starch microspheres for hepatocellular carcinoma. J Gastroenterol 2012;47:715-22.
23. Gruber-Rouh T, Schmitt C, Naguib NNN, et al. Transarterial chemoembolization (TACE) using mitomycin and lipiodol with or without degradable starch microspheres for hepatocellular carcinoma: comparative study. BMC Cancer 2018;18:188.
24. Vogl TJ, Langenbach MC, Hammerstingl R, Albrecht MH, Chatterjee AR, Gruber-Rouh T. Evaluation of two different transarterial chemoembolization protocols using Lipiodol and degradable starch microspheres in therapy of hepatocellular carcinoma: a prospective trial. Hepatol Int 2021;15:685-94.
25. Maeda N, Verret V, Moine L, et al. Targeting and recanalization after embolization with calibrated resorbable microspheres versus hand-cut gelatin sponge particles in a porcine kidney model. J Vasc Interv Radiol 2013;24:1391-8.
26. Katsumori T, Kasahara T. The size of gelatin sponge particles: differences with preparation method. Cardiovasc Intervent Radiol 2006;29:1077-83.
27. Carr BI, Zajko A, Bron K, Orons P, Sammon J, Baron R. Phase II study of Spherex (degradable starch microspheres) injected into the hepatic artery in conjunction with doxorubicin and cisplatin in the treatment of advanced-stage hepatocellular carcinoma: interim analysis. Semin Oncol 1997;24:S6-97.
28. Furuse J, Ishii H, Satake M, et al. Pilot study of transcatheter arterial chemoembolization with degradable starch microspheres in patients with hepatocellular carcinoma. Am J Clin Oncol 2003;26:159-64.
29. Gross A, Albrecht T. Transarterial chemoembolisation (TACE) with degradable starch microspheres (DSM) and anthracycline in patients with locally extensive hepatocellular carcinoma (HCC): safety and efficacy. Cardiovasc Intervent Radiol 2020;43:402-10.
30. Haubold J, Reinboldt MP, Wetter A, et al. DSM-TACE of HCC: evaluation of tumor response in patients ineligible for other systemic or loco-regional therapies. Rofo 2020;192:862-9.
31. Iezzi R, Pompili M, Rinninella E, et al. HepatoCatt Study Group. TACE with degradable starch microspheres (DSM-TACE) as second-line treatment in HCC patients dismissing or ineligible for sorafenib. Eur Radiol 2019;29:1285-92.
32. Takayasu K, Arii S, Ikai I, et al. Liver Cancer Study Group of Japan. Overall survival after transarterial lipiodol infusion chemotherapy with or without embolization for unresectable hepatocellular carcinoma: propensity score analysis. AJR Am J Roentgenol 2010;194:830-7.
33. Yamasaki T, Hamabe S, Saeki I, et al. A novel transcatheter arterial infusion chemotherapy using iodized oil and degradable starch microspheres for hepatocellular carcinoma: a prospective randomized trial. J Gastroenterol 2011;46:359-66.
34. Idée JM, Guiu B. Use of Lipiodol as a drug-delivery system for transcatheter arterial chemoembolization of hepatocellular carcinoma: a review. Crit Rev Oncol Hematol 2013;88:530-49.
35. Renzulli M, Peta G, Vasuri F, et al. Standardization of conventional chemoembolization for hepatocellular carcinoma. Ann Hepatol 2021;22:100278.
36. Kim DY, Ryu HJ, Choi JY, et al. Radiological response predicts survival following transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma. Aliment Pharmacol Ther 2012;35:1343-50.
37. Kim S, Kim HY, Lee SL, Ku YM, Won YD, Kim CW. Lipiodol pneumonitis following transcatheter arterial chemoembolization for hepatocellular carcinoma. J Liver Cancer 2020;20:60-6.
38. Burroughs A, Hochhauser D, Meyer T. Systemic treatment and liver transplantation for hepatocellular carcinoma: two ends of the therapeutic spectrum. Lancet Oncol 2004;5:409-18.
39. Marelli L, Stigliano R, Triantos C, et al. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? Cardiovasc Intervent Radiol 2007;30:6-25.
40. Jordan O, Denys A, De Baere T, Boulens N, Doelker E. Comparative study of chemoembolization loadable beads:
41. Namur J, Wassef M, Millot JM, Lewis AL, Manfait M, Laurent A. Drug-eluting beads for liver embolization: concentration of doxorubicin in tissue and in beads in a pig model. J Vasc Interv Radiol 2010;21:259-67.
42. Ha BY, Ahmed A, Sze DY, et al. Long-term survival of patients with unresectable hepatocellular carcinoma treated with transcatheter arterial chemoinfusion. Aliment Pharmacol Ther 2007;26:839-46.
43. Daniels JR, Wallman M. Subselective intra-arterial chemotherapy infusion in the treatment of hepatocellular carcinoma. Semin Oncol 2010;37:83-8.
44. Kim JH, Yoon HK, Kim SY, et al. Transcatheter arterial chemoembolization
45. Schicho A, Hellerbrand C, Krüger K, et al. Impact of different embolic agents for transarterial chemoembolization (TACE) procedures on systemic vascular endothelial growth factor (VEGF) levels. J Clin Transl Hepatol 2016;4:288-92.
46. Sergio A, Cristofori C, Cardin R, et al. Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness. Am J Gastroenterol 2008;103:914-21.
47. Chegai F, Orlacchio A, Merolla S, Monti S, Mannelli L. Intermediate hepatocellular carcinoma: the role of transarterial therapy. Hepat Oncol 2015;2:399-408.
48. Brown KT, Do RK, Gonen M, et al. Randomized trial of hepatic artery embolization for hepatocellular carcinoma using doxorubicin-eluting microspheres compared with embolization with microspheres alone. J Clin Oncol 2016;34:2046-53.
49. Ludwig JM, Iezzi R, Theysohn JM, Albrecht T, Posa A, Gross A. European multicenter study on degradable starch microsphere TACE: the digestible way to conquer HCC in patients with high tumor burden. Cancers (Basel) 2021;13:5122.
50. Dettmer A, Kirchhoff TD, Gebel M, et al. Combination of repeated single-session percutaneous ethanol injection and transarterial chemoembolisation compared to repeated single-session percutaneous ethanol injection in patients with non-resectable hepatocellular carcinoma. World J Gastroenterol 2006;12:3707-15.
51. Kirchhoff TD, Bleck JS, Dettmer A, et al. Transarterial chemoembolization using degradable starch microspheres and iodized oil in the treatment of advanced hepatocellular carcinoma: evaluation of tumor response, toxicity, and survival. Hepatobiliary Pancreat Dis Int 2007;6:259-66.
52. Murata S, Tajima H, Ichikawa K, et al. Oily chemoembolization combined with degradable starch microspheres for HCC with cirrhosis. Hepatogastroenterology 2008;55:1041-6.
53. Schicho A, Pereira PL, Haimerl M, et al. Transarterial chemoembolization (TACE) with degradable starch microspheres (DSM) in hepatocellular carcinoma (HCC): multi-center results on safety and efficacy. Oncotarget 2017;8:72613-20.
54. Orlacchio A, Chegai F, Roma S, Merolla S, Bosa A, Francioso S. Degradable starch microspheres transarterial chemoembolization (DSMs-TACE) in patients with unresectable hepatocellular carcinoma (HCC): long-term results from a single-center 137-patient cohort prospective study. Radiol Med 2020;125:98-106.
55. Yildiz I, Deniz S, Ozer A, Caliskan K. Trans-arterial chemoembolization with 50 μm degradable starch microspheres versus
56. Minici R, Ammendola M, Manti F, et al. Safety and efficacy of degradable starch microspheres transcatheter arterial chemoembolization as a bridging therapy in patients with early stage hepatocellular carcinoma and child-pugh stage B eligible for liver transplant. Front Pharmacol 2021;12:634084.
57. Mohr I, Vogeler M, Pfeiffenberger J, et al. Clinical effects and safety of different transarterial chemoembolization methods for bridging and palliative treatments in hepatocellular carcinoma. J Cancer Res Clin Oncol 2022;148:3163-74.
58. Minici R, Ammendola M, Manti F, et al. Safety and efficacy of degradable starch microspheres transcatheter arterial chemoembolization (DSM-TACE) in the downstaging of intermediate-stage hepatocellular carcinoma (HCC) in patients with a child-pugh score of 8-9. Front Pharmacol 2021;12:634087.
59. Niessen C, Unterpaintner E, Goessmann H, et al. Degradable starch microspheres versus ethiodol and doxorubicin in transarterial chemoembolization of hepatocellular carcinoma. J Vasc Interv Radiol 2014;25:240-7.
60. Auer TA, Jonczyk M, Collettini F, et al. Trans-arterial chemoembolization with degradable starch microspheres (DSM-TACE) versus selective internal radiation therapy (SIRT) in multifocal hepatocellular carcinoma. Acta Radiol 2021;62:313-21.
61. Vincenzi B, Di Maio M, Silletta M, et al. Prognostic relevance of objective response according to EASL criteria and mRECIST criteria in hepatocellular carcinoma patients treated with loco-regional therapies: a literature-based meta-analysis. PLoS One 2015;10:e0133488.
62. Chang WC, Hsu HH, Chiu SH, et al. Transcatheter arterial chemoembolization with drug-eluting beads for the treatment of hepatocellular carcinoma: recommended selection for small-caliber (< 100 μm) beads. J Hepatocell Carcinoma 2021;8:937-49.
63. Lee IJ, Lee JH, Lee YB, et al. Effectiveness of drug-eluting bead transarterial chemoembolization versus conventional transarterial chemoembolization for small hepatocellular carcinoma in Child-Pugh class A patients. Ther Adv Med Oncol 2019;11:1758835919866072.
64. Llovet JM, Ricci S, Mazzaferro V, et al. SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-90.
65. Kalva SP, Pectasides M, Yeddula K, Ganguli S, Blaszkowsky LS, Zhu AX. Factors affecting survival following chemoembolization with doxorubicin-eluting microspheres for inoperable hepatocellular carcinoma. J Vasc Interv Radiol 2013;24:257-65.
66. Zhang Y, Zhang M, Chen M, et al. Association of sustained response duration with survival after conventional transarterial chemoembolization in patients with hepatocellular carcinoma. JAMA Netw Open 2018;1:e183213.
67. Granito A, Facciorusso A, Sacco R, et al. TRANS-TACE: prognostic role of the transient hypertransaminasemia after conventional chemoembolization for hepatocellular carcinoma. J Pers Med 2021;11:1041.
68. Lammer J, Malagari K, Vogl T, et al. PRECISION V Investigators. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol 2010;33:41-52.
69. Guiu B, Deschamps F, Aho S, et al. Liver/biliary injuries following chemoembolisation of endocrine tumours and hepatocellular carcinoma: lipiodol
70. Woo S, Chung JW, Hur S, et al. Liver abscess after transarterial chemoembolization in patients with bilioenteric anastomosis: frequency and risk factors. AJR Am J Roentgenol 2013;200:1370-7.
71. Spina JC, Ulla M, Yeyati EL, et al. MDCT findings after hepatic chemoembolization with DC-beads: what the radiologist needs to know. Abdom Imaging 2013;38:778-84.
72. Dhamija E, Paul SB, Gamanagatti SR, Acharya SK. Biliary complications of arterial chemoembolization of hepatocellular carcinoma. Diagn Interv Imaging 2015;96:1169-75.
73. Salgia R, Mendiratta V. The Multidisciplinary Management of Hepatocellular Carcinoma. Clin Liver Dis (Hoboken) 2021;17:405-8.
74. Gadsden MM, Kaplan DE. Multidisciplinary approach to HCC management: how can this be done? Dig Dis Sci 2019;64:968-75.
75. Zhang Y, Weinreb JC, Czeyda-Pommersheim F, Taddei TH. Assessing the impact of referral on multidisciplinary tumor board outcomes in patients with hepatocellular carcinoma. J Am Coll Radiol 2020;17:1636-43.
76. Vitale A, Trevisani F, Farinati F, Cillo U. Treatment of hepatocellular carcinoma in the precision medicine era: from treatment stage migration to therapeutic hierarchy. Hepatology 2020;72:2206-18.
77. Leoni S, Piscaglia F, Serio I, et al. Adherence to AASLD guidelines for the treatment of hepatocellular carcinoma in clinical practice: experience of the Bologna Liver Oncology Group. Dig Liver Dis 2014;46:549-55.
78. Jogi S, Varanai R, Bantu SS, Manne A. Selecting the first line treatment in non-metastatic hepatocellular carcinoma - comparing clinical practice guidelines. Oncol Rev 2020;14:515.
79. Sangiovanni A, Triolo M, Iavarone M, et al. Multimodality treatment of hepatocellular carcinoma: How field practice complies with international recommendations. Liver Int 2018;38:1624-34.
80. Dionisi F, Brolese A, Siniscalchi B, et al. Clinical results of active scanning proton therapy for primary liver tumors. Tumori 2021;107:71-9.
81. Colliez F, Gallez B, Jordan BF. Assessing tumor oxygenation for predicting outcome in radiation oncology: a review of studies correlating tumor hypoxic status and outcome in the preclinical and clinical settings. Front Oncol 2017;7:10.
82. Kennedy AS, Sangro B. Nonsurgical treatment for localized hepatocellular carcinoma. Curr Oncol Rep 2014;16:373.
83. Akateh C, Black SM, Conteh L, et al. Neoadjuvant and adjuvant treatment strategies for hepatocellular carcinoma. World J Gastroenterol 2019;25:3704-21.
84. Lei J, Zhong J, Yan L, et al. Preoperative adjuvant transarterial chemoembolization cannot improve the long term outcome of radical therapies for hepatocellular carcinoma. Sci Rep 2017;7:41624.
85. Qi X, Liu L, Wang D, Li H, Su C, Guo X. Hepatic resection alone versus in combination with pre- and post-operative transarterial chemoembolization for the treatment of hepatocellular carcinoma: a systematic review and meta-analysis. Oncotarget 2015;6:36838-59.
86. Tsutsui R, Nagamatsu H, Itano O, et al. Neoadjuvant hepatic arterial infusion chemotherapy for resectable hepatocellular carcinomas. Hepatoma Res 2018;4:13.
87. Chen QW, Ying HF, Gao S, et al. Radiofrequency ablation plus chemoembolization versus radiofrequency ablation alone for hepatocellular carcinoma: a systematic review and meta-analysis. Clin Res Hepatol Gastroenterol 2016;40:309-14.
88. Jacob R, Turley F, Redden DT, et al. Adjuvant stereotactic body radiotherapy following transarterial chemoembolization in patients with non-resectable hepatocellular carcinoma tumours of ≥ 3 cm. HPB (Oxford) 2015;17:140-9.
89. Kudo M, Ueshima K, Ikeda M, et al. TACTICS study group. Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial. Gut 2020;69:1492-501.
90. Ogasawara S, Ooka Y, Koroki K, et al. Switching to systemic therapy after locoregional treatment failure: definition and best timing. Clin Mol Hepatol 2020;26:155-62.
91. Vogel A, Martinelli E. ESMO Guidelines Committee. Electronic address: [email protected], ESMO Guidelines Committee. Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines. Ann Oncol 2021;32:801-5.
